Duchenne Muscular Dystrophy Drug Poised To Enter Market
San Rafael, California-based biotechnology company BioMarin Pharmaceutical’s experimental drug drisapersen, which is under development as a new treatment for Duchenne muscular dystrophy (DMD), is ready to enter the market pending approval by the U.S. Food and Drug Administration (FDA). According to The Muscular Dystrophy Association (MDA) — a global…